Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S (2018) Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 67(3):1132–1149. https://doi.org/10.1002/hep.29496

Article  PubMed  Google Scholar 

Chen J, Fan Y, Cui B, Li X, Yu Y, Du Y, Chen Q, Feng Y, Zhang P (2018) HMGN2: an antitumor effector molecule of γδT cells. J Immunother 41(3):118–124. https://doi.org/10.1097/CJI.0000000000000211

Article  CAS  PubMed  Google Scholar 

de Paz AM, Ausió J (2016) HMGNs: the enhancer charmers. BioEssays 38(3):226–231. https://doi.org/10.1002/bies.201500157

Article  CAS  Google Scholar 

Eliason S, Su D, Pinho F, Sun Z, Zhang Z, Li X, Sweat M, Venugopalan SR, He B, Bustin M, Amendt BA (2022) HMGN2 represses gene transcription via interaction with transcription factors Lef-1 and Pitx2 during amelogenesis. J Biol Chem 298(9):102295. https://doi.org/10.1016/j.jbc.2022.102295

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finnberg N, El-Deiry WS (2008) TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 7(11):1525–1528. https://doi.org/10.4161/cc.7.11.5975

Article  CAS  PubMed  Google Scholar 

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301–1314. https://doi.org/10.1016/S0140-6736(22)01200-4

Article  PubMed  Google Scholar 

Ganesan P, Kulik LM (2023) Hepatocellular carcinoma: new developments. Clin Liver Dis 27(1):85–102. https://doi.org/10.1016/j.cld.2022.08.004

Article  PubMed  Google Scholar 

Gerlitz G (2010) HMGNs, DNA repair and cancer. Biochim Biophys Acta 1799(1–2):80–85. https://doi.org/10.1016/j.bbagrm.2009.10.007

Article  CAS  PubMed  Google Scholar 

Hagiwara S, Nishida N, Kudo M (2023) Advances in immunotherapy for hepatocellular carcinoma. Cancers 15(7):2070. https://doi.org/10.1038/s41575-021-00438-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartke J, Johnson M, Ghabril M (2017) The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol 34(2):153–159. https://doi.org/10.1053/j.semdp.2016.12.011

Article  PubMed  Google Scholar 

Hu A, Dong X, Liu X, Zhang P, Zhang Y, Su N, Chen Q, Feng Y (2014) Nucleosome-binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma. Oncol Lett 7(1):115–120. https://doi.org/10.3892/ol.2013.1665

Article  CAS  PubMed  Google Scholar 

Isoai A, Giga-Hama Y, Shinkai K, Mukai M, Akedo H, Kumagai H (1992) Tumor invasion-inhibiting factor 2: primary structure and inhibitory effect on invasion in vitro and pulmonary metastasis of tumor cells. Cancer Res 52(6):1422–1426

CAS  PubMed  Google Scholar 

Li H, Wu X, Bu D, Wang L, Xu X, Wang Y, Liu Y, Zhu P (2022) Recombinant jurkat cells (HMGN2-T cells) secrete cytokines and inhibit the growth of tumor cells. J Mol Histol 53(4):741–751. https://doi.org/10.1007/s10735-022-10084-8

Article  CAS  PubMed  Google Scholar 

Liu D, Song T (2021) Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci Trends 15(3):142–147. https://doi.org/10.5582/bst.2021.01083

Article  PubMed  Google Scholar 

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262

Article  CAS  PubMed  Google Scholar 

Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A (2022) Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 3(4):386–401. https://doi.org/10.1038/s43018-022-00357-2

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Shen H, Huang W, He S, Chen J, Zhang D, Shen Y, Sun Y (2021) Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discov 7(1):359. https://doi.org/10.1038/s41420-021-00747-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moga TV, Popescu A, Sporea I, Danila M, David C, Gui V, Iacob N, Miclaus G, Sirli R (2017) Is contrast enhanced ultrasonography a useful tool in a beginner’s hand? How much can a computer assisted diagnosis prototype help in characterizing the malignancy of focal liver lesions? Med Ultrason 19(3):252–258. https://doi.org/10.11152/mu-936

Article  PubMed  Google Scholar 

Prosperi JR, Goss KH (2014) Targeting loss of tumor suppressors for cancer therapeutics. Curr Drug Targets 15(1):1. https://doi.org/10.2174/138945011501140115104533

Article  CAS  PubMed  Google Scholar 

Sim HW, Knox J (2018) Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer 42(1):40–48. https://doi.org/10.1016/j.currproblcancer.2017.10.007

Article  PubMed  Google Scholar 

Su L, Hu A, Luo Y, Zhou W, Zhang P, Feng Y (2014) HMGN2, a new anti-tumor effector molecule of CD8+ T cells. Mol Cancer 13:178. https://doi.org/10.1186/1476-4598-13-178

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F (2022) Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a review. Front Oncol 12:980214. https://doi.org/10.3389/fonc.2022.980214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5(1):87. https://doi.org/10.1038/s41392-020-0187-x

Article  PubMed  PubMed Central  Google Scholar 

Wei D, Zhang P, Zhou M, Feng Y, Chen Q (2014) HMGN2 protein inhibits the growth of infected T24 cells in vitro. J Cancer Res Ther 10(2):299–304. https://doi.org/10.4103/0973-1482.136577

Article  CAS  PubMed  Google Scholar 

Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F, Yi D (2023) Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma. Front Oncol 13:1197698. https://doi.org/10.3389/fonc.2023.1197698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu E, Jiang H, Lin T, Meng Y, Ma X, Yin J, Ma J, Zhou X (2020) Exogenous HMGN2 inhibits the migration and invasion of osteosarcoma cell lines. Transl Cancer Res 9(3):1795–1805. https://doi.org/10.21037/tcr.2020.02.25

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, Winkler S, Houben P, Schultze D, Hatano E, Schemmer P (2013) Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma—systematic review and meta-analysis. Cancer Med 2(6):862–871. https://doi.org/10.1002/cam4.150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Liao Y, Tang L (2019) MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res 38(1):53. https://doi.org/10.1186/s13046-019-1059-5

Article  PubMed  PubMed Central